Oh no, not Luke - he was one of my favourites - always a smile on his dial.
Redundancies are never fun, especially when the Company/Team is as close-knit as DRE, but I'm sure Luke will be ok, especially as he had a good part in the Yin discovery, and a world-class discovery goes down just fine on a resume.
On the other hand, it looks like the new strategy is already in motion.
Concentrating on the A-Z metals that are at Mangaroon, JV-ing/dealing out the other projects, meaning that they need less geos.
To state the obvious, Partners will pay for exploration on the other projects, meaning a lot less expenditure for DRE as no exploration/tenement costs for other projects, plus less geo costs.
Good for the company but unfortunate if you're on the other end of a redundancy (all the best to Luke from all shareholders, and pretty sure he's a shareholder too as most of the Team went into that 10c CR and/or exercised their options at much higher prices than current SP).
Onward and upwards, and hopefully good news not far away.
Cheers,
GB.
- Forums
- ASX - By Stock
- DRE
- Ann: Annual Report to Shareholders - 30 June 2024
Ann: Annual Report to Shareholders - 30 June 2024, page-31
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DRE (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.79M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 3756483 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 3102661 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 3756483 | 0.016 |
26 | 6914950 | 0.015 |
14 | 3691354 | 0.014 |
12 | 8153503 | 0.013 |
4 | 2085304 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 3102661 | 13 |
0.018 | 3911272 | 14 |
0.019 | 3514582 | 13 |
0.020 | 2338716 | 12 |
0.021 | 2087380 | 6 |
Last trade - 11.10am 12/11/2024 (20 minute delay) ? |
Featured News
DRE (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online